Login / Signup

Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.

Yuda ZhangFanxu ZengShixuan PengYangqian ChenWenjuan JiangZhan WangLi DengZhe HuangHaoyue QinHuan YanXing ZhangLin ZhangNong YangQian GongLiang ZengYong-Chang Zhang
Published in: Expert review of respiratory medicine (2023)
KRAS mutations have posed a significant challenge in the treatment of advanced non-small cell lung cancer (NSCLC) over the past few decades. However, the emergence of immunotherapy and KRAS inhibitors, such as Sotorasib (AMG 510) and Adagrasib (MRTX849), has marked a new era in cancer therapy. As more research and clinical trials continue, we anticipate the development of more effective treatment strategies and better options for lung cancer patients.
Keyphrases
  • advanced non small cell lung cancer
  • wild type
  • epidermal growth factor receptor
  • cancer therapy
  • clinical trial
  • drug delivery
  • tyrosine kinase
  • small cell lung cancer
  • open label
  • smoking cessation